Chi Sheng Chemical
Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. Its product portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic … Read more
Chi Sheng Chemical (4111) - Total Liabilities
Latest total liabilities as of June 2025: NT$550.20 Million TWD
Based on the latest financial reports, Chi Sheng Chemical (4111) has total liabilities worth NT$550.20 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chi Sheng Chemical - Total Liabilities Trend (2017–2024)
This chart illustrates how Chi Sheng Chemical's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chi Sheng Chemical Competitors by Total Liabilities
The table below lists competitors of Chi Sheng Chemical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Finger Inc.
KQ:163730
|
Korea | ₩21.07 Billion |
|
SUN KWANG CO.Ltd
KQ:003100
|
Korea | ₩258.43 Billion |
|
LumenRadio AB
ST:LUMEN
|
Sweden | Skr70.90 Million |
|
Sajodongaone Co Ltd
KO:008040
|
Korea | ₩194.43 Billion |
|
Lake Shore Bancorp Inc
NASDAQ:LSBK
|
USA | $603.50 Million |
|
NEOWIZ HOLDINGS Corporation
KQ:042420
|
Korea | ₩150.12 Billion |
|
Vivani Medical Inc.
NASDAQ:VANI
|
USA | $23.74 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Chi Sheng Chemical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chi Sheng Chemical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chi Sheng Chemical (2017–2024)
The table below shows the annual total liabilities of Chi Sheng Chemical from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$475.08 Million | -13.15% |
| 2023-12-31 | NT$547.04 Million | -5.42% |
| 2022-12-31 | NT$578.38 Million | +3.46% |
| 2021-12-31 | NT$559.04 Million | +36.04% |
| 2020-12-31 | NT$410.93 Million | -8.73% |
| 2019-12-31 | NT$450.25 Million | -1.74% |
| 2018-12-31 | NT$458.24 Million | +6.97% |
| 2017-12-31 | NT$428.39 Million | -- |